Literature DB >> 28162910

Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.

Thomas Simon1, Teresa Gagliano2, Georgios Giamas3.   

Abstract

Over recent decades anti-angiogenic therapies (AATs) have produced promising results in the treatment of different malignancies. Unfortunately, resistance often develops and patients ultimately relapse. In an attempt to elucidate the causes of recurrence, most studies have focused on tumor responses to hypoxic conditions induced by AAT. However, strategies targeting these mechanisms of resistance are still failing to improve treatments. Furthermore, a potential direct impact of AAT on tumor cells cannot be overlooked. This review provides a novel overview of the different aspects of the tumor cell response to AAT. Conflicting data regarding the nature of this effect are discussed and reconciled, thus providing new insight into the discussion of tumor recurrence despite AAT. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28162910     DOI: 10.1016/j.molmed.2017.01.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  24 in total

Review 1.  PET Imaging of Receptor Tyrosine Kinases in Cancer.

Authors:  Weijun Wei; Dalong Ni; Emily B Ehlerding; Quan-Yong Luo; Weibo Cai
Journal:  Mol Cancer Ther       Date:  2018-08       Impact factor: 6.261

Review 2.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

3.  Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization.

Authors:  Tongqiang Li; Qin Shi; Jiacheng Liu; Yingliang Wang; Chen Zhou; Chaoyang Wang; Shuguang Ju; Songjiang Huang; Chongtu Yang; Yang Chen; Yaowei Bai; Bin Xiong
Journal:  J Hepatocell Carcinoma       Date:  2021-12-03

4.  Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia.

Authors:  Mohsen Shahmoradi; Fatemeh Banisharif-Dehkordi; Mahnoush Kouhihabibidehkordi; Mahdi GhatrehSamani; Mohammad-Saied Jami; Hedayatollah Shirzad; Batoul Pourgheysari
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

5.  An Improved In Vivo Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay.

Authors:  Naside Mangir; Ahtasham Raza; John W Haycock; Christopher Chapple; Sheila Macneil
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

6.  MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells.

Authors:  Xiaorui Wang; Zhongsheng Tong; Hong Liu
Journal:  Onco Targets Ther       Date:  2019-09-18       Impact factor: 4.147

Review 7.  Autophagy in Viral Development and Progression of Cancer.

Authors:  Alejandra Suares; María Victoria Medina; Omar Coso
Journal:  Front Oncol       Date:  2021-03-08       Impact factor: 6.244

8.  Aquaporin-1 inhibition reduces metastatic formation in a mouse model of melanoma.

Authors:  Laura Simone; Concetta Domenica Gargano; Francesco Pisani; Antonio Cibelli; Maria Grazia Mola; Antonio Frigeri; Maria Svelto; Grazia Paola Nicchia
Journal:  J Cell Mol Med       Date:  2017-10-17       Impact factor: 5.310

Review 9.  Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.

Authors:  Xinqiang Han; Yun Zhou; Wendi Liu
Journal:  NPJ Precis Oncol       Date:  2017-09-12

Review 10.  Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.

Authors:  Chloe J Peach; Viviane W Mignone; Maria Augusta Arruda; Diana C Alcobia; Stephen J Hill; Laura E Kilpatrick; Jeanette Woolard
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.